400 Interpace Parkway Parsippany NJ 07054, Parsippany, NJ · MICHAEL BRZICA
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2026 | TEVA PHARMACEUTICALS USA INC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $1,100,000 | |
| 2025 | TEVA PHARMACEUTICALS USA INC |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $360,000 | |
| 2025 | TEVA PHARMACEUTICALS USA INC |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $460,000 | |
| 2025 | TEVA PHARMACEUTICALS USA INC |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | $1,390,000 | |
| 2025 | TEVA PHARMACEUTICALS USA INC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $1,390,000 | |
| 2025 | TEVA PHARMACEUTICALS USA INC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $310,000 | |
| 2024 | TEVA PHARMACEUTICALS USA INC |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $360,000 | |
| 2024 | TEVA PHARMACEUTICALS USA INC |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $310,000 | |
| 2024 | TEVA PHARMACEUTICALS USA INC |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $250,000 | |
| 2024 | TEVA PHARMACEUTICALS USA INC |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $1,330,000 |
| Client | Filings | Total Income |
|---|---|---|
| TEVA PHARMACEUTICALS USA INC | 87 | — |
| Name | Disclosed Prior Position |
|---|---|
| SUSIE AHN | L.A., Rep. Xavier Becerra (2000-01) |
| DEBRA BARRETT | N/A |
| MICHAEL BRZICA | Legislative Counsel, Rep. Lee Terry (2007-2009) |
| ROBERT JOHN CLARK | Staff Assist., Rep. Frank Pallone (2003-04) |
| SHANNON DZUBIN | |
| GRANT ERDEL | Rep. Charles Bass, Legislative Director (2011-12) |
| ROBERT FALB | Rep. Visclosky, LA & LD (until 1991) |
| JAMES M. FENTON | Chief of Staff, Leg. Director, & Staff Assist. to Sen. Chris Dodd, and Prof. Staff Member of Senate HELP Subcommittee o… |
| DOLLY A JUDGE | |
| BEENA S PATEL | |
| COLMAN BRENDAN RAGAN | |
| DAVID SANDERS | Patent & Trademark Office - Government Affairs |
| TERRI STEWART | |
| ASHLEA D THOMAS | N/A |